|Articles|May 7, 2023
- Pharmaceutical Executive: May 2023
- Volume 43
- Issue 5
Pharmaceutical Executive, May 2023 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive May 2023 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 3 years ago
From Science to Strategy | 2023 Emerging Pharma Leaderalmost 3 years ago
Committed to the Cause | 2023 Emerging Pharma Leaderalmost 3 years ago
A Knack for Problem-Solving | 2023 Emerging Pharma Leaderalmost 3 years ago
Mission-Fueled Mindset | 2023 Emerging Pharma Leaderalmost 3 years ago
Rejuvenating Lives | 2023 Emerging Pharma Leaderalmost 3 years ago
Optimized for Growth? Revenue Management in Pharmaalmost 3 years ago
Preparing for the End of the COVID Health Emergencyalmost 3 years ago
AI is a Tool, Not a Replacement for Employeesalmost 3 years ago
Ratings and Rankings: ESG Fundamentals for Pharma LeadersNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Bayer Shares Briefly Dip After Activist Investor Offloads Millions of Dollars in Company Stock
2
Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio
3
Pharma M&A Roundup: Merck to Acquire Terns Pharmaceuticals, Shionogi to Acquire 50% of Apnimed’s Ownership of Shionogi-Apnimed Sleep Science
4
FDA Sends Warning Letter to ImmunityBio for Misleading Claims in Advertisement
5

